Amicus Therapeutics (NASDAQ:FOLD) and Clearside Biomedical (NASDAQ:CLSD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Institutional and Insider Ownership
17.7% of Clearside Biomedical shares are owned by institutional investors. 2.5% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Clearside Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Amicus Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
This table compares Amicus Therapeutics and Clearside Biomedical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Amicus Therapeutics and Clearside Biomedical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amicus Therapeutics currently has a consensus price target of $20.50, suggesting a potential upside of 63.87%. Clearside Biomedical has a consensus price target of $6.00, suggesting a potential upside of 203.03%. Given Clearside Biomedical’s higher probable upside, analysts plainly believe Clearside Biomedical is more favorable than Amicus Therapeutics.
Earnings and Valuation
This table compares Amicus Therapeutics and Clearside Biomedical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amicus Therapeutics||$182.24 million||17.69||-$356.39 million||($1.31)||-9.55|
|Clearside Biomedical||$2.17 million||40.94||-$30.77 million||($0.81)||-2.44|
Clearside Biomedical has lower revenue, but higher earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
About Clearside Biomedical
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.